Stockscreener 앱 받기
12.21
3.39%
0.40
시간 외 거래:
12.38
0.17
+1.39%
전일 마감가:
$11.81
열려 있는:
$11.81
하루 거래량:
22,746
Relative Volume:
0.42
시가총액:
$60.83M
수익:
-
순이익/손실:
$-12.49M
주가수익비율:
-4.1183
EPS:
-2.9648
순현금흐름:
$-5.93M
1주 성능:
+0.16%
1개월 성능:
+13.90%
6개월 성능:
+4.27%
1년 성능:
+63.02%
1일 변동 폭
$11.81
$12.63
1주일 범위
$11.62
$12.72
52주 변동 폭
$6.80
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
12.21 | 62.45M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Number of shareholders of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Number of shareholders of MiNK Therapeutics, Inc. – FWB:6Q40 - TradingView
INKT Technical Analysis & Stock Price Forecast - Intellectia AI
MiNK Therapeutics (INKT) Rallies 1.19% as Support Holds Firm Near $11.72IV Contraction - newsline.com
INKT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor SentimentProfit Warning Alert - newsline.com
Discipline and Rules-Based Execution in INKT Response - Stock Traders Daily
Number of shareholders of MiNK Therapeutics, Inc. – LS:A40ZAV - TradingView
INKT Q1 2026 Earnings: EPS Beat on Narrower Loss, But Stock Drops 5%Quarterly Earnings Report - newsline.com
MiNK Therapeutics (INKT) Pulls Back Sharply: Support Test LoomsStrangle Setup - newsline.com
Insider Sell: Barbara Ryan Sells 1,500 Shares of MiNK Therapeuti - GuruFocus
MiNK Therapeutics Q1 earnings call highlights - MSN
Mink Therapeutics director Barbara Ryan sells $19,141 in stock By Investing.com - Investing.com Canada
Mink Therapeutics director Barbara Ryan sells $19,141 in stock - Investing.com India
Director at MiNK Therapeutics (NASDAQ: INKT) sells 1,500 shares - Stock Titan
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - The Manila Times
How to join MiNK Therapeutics’ June 17 virtual shareholder meeting - Stock Titan
MiNK Therapeutics (INKT) Holds Near $12.0 as Trading Volume Remains ModestIchimoku Kumo Break - newsline.com
MiNK Therapeutics (NASDAQ: INKT) director granted RSU-based stock awards for board service - Stock Titan
MiNK Therapeutics (INKT) director granted stock units instead of cash retainers - Stock Titan
MiNK Therapeutics (INKT) director receives RSUs for board pay - Stock Titan
Director at MiNK Therapeutics (NASDAQ: INKT) receives RSU board compensation - Stock Titan
MiNK Therapeutics (NASDAQ: INKT) director receives RSU grants instead of cash retainers - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
Behavioral Patterns of INKT and Institutional Flows - Stock Traders Daily
INKT Begins Phase 2 Trial for Severe Acute Lung Injury Treatment - GuruFocus
INKT Q1 2026 Earnings: Better-Than-Expected Loss Drives 15.9% Stock RallyEPS Growth Report - thelegaladvocate.com
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - Investing News Network
Mink Therapeutics Doses First Patient in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness - marketscreener.com
Why is Mink Therapeutics stock surging today? By Investing.com - Investing.com Canada
MiNK Therapeutics doses first patient in lung injury trial - Investing.com UK
MiNK Therapeutics doses first patient in lung injury trial By Investing.com - Investing.com Nigeria
New cell therapy tested in Ukraine ICU for severe acute lung injury - Stock Titan
MiNK Therapeutics Q1 2026 Earnings: Narrowed Loss Exceeds Expectations Amid Clinical ProgressEarnings Deceleration Risk - The Legal Advocate
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - Investing News Network
MiNK Therapeutics Reports Promising Results from Phase 2 Trial of agenT-797 and N-803 Combination Therapy for Coccidioides immitis Infection - Quiver Quantitative
MiNK Therapeutics Reports New Data on agenT-797, an - GlobeNewswire
MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026 - MSN
MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co. - Moomoo
(INKT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate - Yahoo Finance
User | bigspringherald.comMiNK Therapeutics, Inc.Common Stock (Nasdaq:INKT) Stock Quote - FinancialContent
About Us - FinancialContent
Mink Therapeutics’ Earnings Call: High Promise, Tight Runway - The Globe and Mail
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2026 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics starts phase 2 trial for lung injury therapy - Investing.com UK
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q1 2026 Earnings Conference - Moomoo
Mink Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mink Therapeutics Inc 주식 (INKT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ryan Barbara | Director |
Mar 10 '26 |
Sale |
15.40 |
1,300 |
20,017 |
20,406 |
| Ryan Barbara | Director |
Mar 09 '26 |
Sale |
10.17 |
200 |
2,034 |
21,706 |
| Ryan Barbara | Director |
Feb 27 '26 |
Sale |
10.86 |
400 |
4,343 |
22,006 |
| Ryan Barbara | Director |
Mar 02 '26 |
Sale |
10.83 |
100 |
1,083 |
21,906 |
2.60%
0.94%
자본화:
|
볼륨(24시간):